Table 1. Demographic Characteristics of Patients with Treatment Naïve Early and Established Rheumatoid Arthritis and Control Individuals with Osteoarthritis.
| ERA, wk 0 (n = 37) | ERA, wk 12 (n = 37) | RA (n = 49) | OA (n = 29) | |
|---|---|---|---|---|
| Demographic characteristic | ||||
| Age (years) | 48.0 ± 15.1 | 48.0 ± 15.1 | 55.9 ± 13.3* | 64.8 ± 10.5 ± § |
| Sex (% female) | 73.0 | 73.0 | 73.5 | 58.6 |
| BMI (kg/m2) | 24.6 ± 3.8 | NA | 25.3± 3.8 | 27.6 ± 3.8 ≠ § |
| Disease activity | ||||
| DAS28-ESR (score) | 5.1 ± 1.4 | 2.6 ± 1.4*** | 4.6 ± 1.5 | - |
| CRP (mg/l) | 13.4 ± 17.0 | 4.3 ± 6.1*** | 25.7 ± 32.6 | 3.6 ± 5.2 ǂ |
| Medication | ||||
| glucocorticoids (%) | - | 83.7 | 63.3 | |
| csDMARDs (%) | - | 94.6 | 83.7 | - |
| bDMARDs (%) | - | 0 | 22.4 | - |
| Autoantibody positivity | ||||
| RFs (%) | 54 | NA | 62 | - |
| Anti-CCP (%) | 51 | NA | 59 | - |
Values are the mean ± SD, unless otherwise stated. BMI, body mass index; DAS, disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; csDMARDs, conventional synthetic disease modifying antirheumatic drugs; bDMARDs, biologic disease modifying antirheumatic drugs; RFs, rheumatoid factors; anti-CCP, anti-cyclic citrullinated peptide; NA, not applicable. Types of bDMARDs: anti-TNFα (etanercept 3x, adalimumab 2x and golimumab 1x), anti-CD20 (rituximab 2x), anti-IL6R (tocilizumab 2x) and anti-IL17 (secukinumab 1x, open phase clinical trial).
*p<0.05 for pairwise comparisons with ERA;
±p<0.001 for pairwise comparisons with ERA;
§p<0.01 for pairwise comparisons with RA;
≠p<0.01 for pairwise comparisons with ERA;
***p<0.001 for pairwise comparisons with ERA wk 0;
ǂp<0.001 for pairwise comparisons with ERA and RA